<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02139007</url>
  </required_header>
  <id_info>
    <org_study_id>F120404006</org_study_id>
    <nct_id>NCT02139007</nct_id>
  </id_info>
  <brief_title>Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study</brief_title>
  <acronym>EDGE</acronym>
  <official_title>Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study evaluating the recruitment strategies for sites and patients, data
      collection instruments, follow-up procedures, administrative processes, and the proposed
      management strategy for the future large scale national trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All Study Sites--Length of Contracting Procedures</measure>
    <time_frame>Length of time Between Clinical Site Recruitment and Contract Execution</time_frame>
    <description>Mean time Between Clinical Site Recruitment and Contract Execution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Study Sites--Length of Time to Site IRB Approval</measure>
    <time_frame>Length of time to site IRB approval</time_frame>
    <description>Mean time to gain site IRB approval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All Study Sites-Length of Time to 1st Participant Enrolled</measure>
    <time_frame>Length of time t for sites to recruit/enroll 1st participant</time_frame>
    <description>Mean time from study initiation to 1st participant enrolled.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Fracture Rate</measure>
    <time_frame>Baseline to 6 months following enrollment</time_frame>
    <description>Patient reported fracture rate at 6 months following enrollment via survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atypical Femoral Fracture</measure>
    <time_frame>Baseline to 6 months following enrollment</time_frame>
    <description>Patient reported fracture rate at 6 months after enrollment via follow-up survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteonecrosis of the Jaw</measure>
    <time_frame>Baseline to 6 months following enrollment</time_frame>
    <description>Patients self report diagnoses of osteonecrosis of the jaw 6 months post enrollment via follow-up survey .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Continuation Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate continuation arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinuation Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate discontinuation arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <arm_group_label>Continuation Arm</arm_group_label>
    <arm_group_label>Discontinuation Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Females 65+

        2.3+ years of alendronate (Fosamax/Binosto) use

        3. Valid social security number

        Exclusion Criteria:

          1. History of any other metabolic bone condition, such as Paget Disease of Bone

          2. Currently receiving treatment for ongoing cancer, excluding non-melanoma skin cancer.

          3. Has significant underlying illness that would be expected to prevent completion of the
             study (e.g., life-threatening disease likely to limit survival to less than 3 years)?

          4. HIV positive

          5. Involved in a conflicting (investigational drug) clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth G Saag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <results_first_submitted>February 8, 2017</results_first_submitted>
  <results_first_submitted_qc>April 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Kenneth Saag, MD, MSc</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sites were selected from 2 practice based research networks based upon self-reporting having a large number of women â‰¥ 65 years of age with a current alendronate prescription. Enrolled patient participants were randomized to continue or discontinue their current prescription. No drug was provided.</recruitment_details>
      <pre_assignment_details>Period 1 refers to the study site recruitment period for the 9 sites that participated in the study. Period 2 refers to the patient recruitment period for the study. Randomization to treatment assignment was at the patient level. Sites recruited patient participants to both arms of the study. Two sites failed to enroll participants in either arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Continuation Arm</title>
          <description>Alendronate continuation arm
Participants were randomized to continue their current alendronate prescription at prescribed dose.</description>
        </group>
        <group group_id="P2">
          <title>Discontinuation Arm</title>
          <description>Alendronate discontinuation arm
Participants were randomized to stop taking their current alendronate prescription.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Study Site Recruitment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Patient Participant Recruitment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Continuation Arm</title>
          <description>Alendronate continuation arm</description>
        </group>
        <group group_id="B2">
          <title>Discontinuation Arm</title>
          <description>Alendronate discontinuation arm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.4" spread="6.7"/>
                    <measurement group_id="B2" value="74.5" spread="5.9"/>
                    <measurement group_id="B3" value="74.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous History of Fracture</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Alendronate Use</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="2.1"/>
                    <measurement group_id="B2" value="5.3" spread="3.1"/>
                    <measurement group_id="B3" value="5.1" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>All Study Sites--Length of Contracting Procedures</title>
        <description>Mean time Between Clinical Site Recruitment and Contract Execution</description>
        <time_frame>Length of time Between Clinical Site Recruitment and Contract Execution</time_frame>
        <population>Nine sites from six states (AL, CO, NM, CT, CA, and PA) participated in this pilot study.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Sites -- Contracting Procedures</title>
            <description>The duration of time from execution of contracts, IRB approval, and to participant recruitment is potential contributor to overall suboptimal recruitment in clinical research. In this pilot study we measured the mean duration of administrative procedures for sites to the first patient enrolled. .</description>
          </group>
        </group_list>
        <measure>
          <title>All Study Sites--Length of Contracting Procedures</title>
          <description>Mean time Between Clinical Site Recruitment and Contract Execution</description>
          <population>Nine sites from six states (AL, CO, NM, CT, CA, and PA) participated in this pilot study.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All Study Sites--Length of Time to Site IRB Approval</title>
        <description>Mean time to gain site IRB approval</description>
        <time_frame>Length of time to site IRB approval</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Study Sites --IRB Approval</title>
            <description>The duration of time from execution of contracts, IRB approval, and to participant recruitment is potential contributor to overall suboptimal recruitment in clinical research. In this pilot study we measured the mean duration of administrative procedures for sites to the first patient enrolled. .</description>
          </group>
        </group_list>
        <measure>
          <title>All Study Sites--Length of Time to Site IRB Approval</title>
          <description>Mean time to gain site IRB approval</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>All Study Sites-Length of Time to 1st Participant Enrolled</title>
        <description>Mean time from study initiation to 1st participant enrolled.</description>
        <time_frame>Length of time t for sites to recruit/enroll 1st participant</time_frame>
        <population>For sites enrolling at least one patient, the average (SD) time from contract execution to the first patient recruited.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Sites-Initiation to the First Participant Recruited</title>
            <description>study initiation to the first participant recruited</description>
          </group>
        </group_list>
        <measure>
          <title>All Study Sites-Length of Time to 1st Participant Enrolled</title>
          <description>Mean time from study initiation to 1st participant enrolled.</description>
          <population>For sites enrolling at least one patient, the average (SD) time from contract execution to the first patient recruited.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Fracture Rate</title>
        <description>Patient reported fracture rate at 6 months following enrollment via survey.</description>
        <time_frame>Baseline to 6 months following enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Arm</title>
            <description>Alendronate continuation arm
Alendronate</description>
          </group>
          <group group_id="O2">
            <title>Discontinuation Arm</title>
            <description>Alendronate discontinuation arm
Alendronate</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Fracture Rate</title>
          <description>Patient reported fracture rate at 6 months following enrollment via survey.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atypical Femoral Fracture</title>
        <description>Patient reported fracture rate at 6 months after enrollment via follow-up survey</description>
        <time_frame>Baseline to 6 months following enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Arm</title>
            <description>Alendronate continuation arm
Alendronate</description>
          </group>
          <group group_id="O2">
            <title>Discontinuation Arm</title>
            <description>Alendronate discontinuation arm
Alendronate</description>
          </group>
        </group_list>
        <measure>
          <title>Atypical Femoral Fracture</title>
          <description>Patient reported fracture rate at 6 months after enrollment via follow-up survey</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Osteonecrosis of the Jaw</title>
        <description>Patients self report diagnoses of osteonecrosis of the jaw 6 months post enrollment via follow-up survey .</description>
        <time_frame>Baseline to 6 months following enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuation Arm</title>
            <description>Alendronate continuation arm
Alendronate</description>
          </group>
          <group group_id="O2">
            <title>Discontinuation Arm</title>
            <description>Alendronate discontinuation arm
Alendronate</description>
          </group>
        </group_list>
        <measure>
          <title>Osteonecrosis of the Jaw</title>
          <description>Patients self report diagnoses of osteonecrosis of the jaw 6 months post enrollment via follow-up survey .</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 6 months following enrollment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Continuation Arm</title>
          <description>Alendronate continuation arm
Alendronate</description>
        </group>
        <group group_id="E2">
          <title>Discontinuation Arm</title>
          <description>Alendronate discontinuation arm
Alendronate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff Foster</name_or_title>
      <organization>UAB</organization>
      <phone>205-996-6086</phone>
      <email>pjfoster@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

